New project to examine the impact of new genomic sequencing technologies

TRANSPERS is leading a four-year, $2.4M project funded by the National Institutes of Health to examine the benefit-risk tradeoffs of new sequencing technologies from a policy perspective. Although these approaches are widely used in a research capacity, sequencing is a new and evolving technology in healthcare, with potential applications in risk assessment, disease diagnosis and treatment decision-making. In order to successfully introduce this technology into routine clinical care, we must first understand and consider the preferences of the relevant stakeholders and the impact on patients, payers, and society — in addition to the scientific evidence that assesses its validity and utility. This TRANSPERS project — one of the first to systematically explore the economic and policy implications of sequencing for the healthcare system and society — will provide critical, early data that can guide the future translation of the technology into clinical care and health policy.


Phillips leads national study of benefit/risk in emergent whole genome sequencing